Teladoc Health, Inc. (TDOC) Q1 2025 Earnings Call Transcript
Teladoc Health, Inc. (NYSE:TDOC ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Corporate Participants Mike Minchak - Head of Investor Relations Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Jessica Tassan - Piper Sandler David Roman - Goldman Sachs Daniel Grosslight - Citi Eduardo Ron - Truist Elizabeth Anderson - Evercore Charles Rhyee - Cowen Operator Good afternoon, thank you for attending today's Teladoc Health First Quarter 2025 Earnings Call. My name is Cole and I'll be the moderator for today's call.
Teladoc (TDOC) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Teladoc (TDOC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
Teladoc (TDOC) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.49 per share a year ago.
Unveiling Teladoc (TDOC) Q1 Outlook: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Teladoc (TDOC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Teladoc (TDOC) Stock Sinks As Market Gains: Here's Why
Teladoc (TDOC) concluded the recent trading session at $7.20, signifying a -0.83% move from its prior day's close.
Teladoc: Back In The Doldrums After Another Tough Year (Rating Downgrade)
Teladoc Health, Inc.'s stock has declined significantly, from a high of $14 per share in February to $7 per share, with ongoing financial struggles and underperformance in key segments. The company reported a net loss of $1 billion in 2024, with declining revenues in its BetterHelp segment and minimal growth in Integrated Care. Despite efforts to cut costs and new initiatives like the Catapult Health acquisition and a partnership with Eli Lilly, Teladoc's value proposition remains unclear.
2 Beaten-Down Stocks to Avoid in the Tariff-Fueled Correction
With equity markets reeling due to President Donald Trump's tariffs, many investors are taking this opportunity to buy shares of top companies on the dip. It's a great strategy, but it's essential to avoid those companies that only look undervalued but actually aren't.
Why Is Teladoc (TDOC) Down 9.9% Since Last Earnings Report?
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock?
Teladoc (TDOC) Flat As Market Sinks: What You Should Know
Teladoc (TDOC) reachead $8.64 at the closing of the latest trading day, reflecting no change compared to its last close.
Teladoc (TDOC) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Teladoc (TDOC) closed at $8.49, marking a +1.19% move from the previous day.
Does Teladoc's $65 Million Acquisition of Catapult Health Make the Stock a Buy?
Telemedicine specialist Teladoc Health (TDOC 1.53%) has been a terrible investment over the past three years. Once the company's pandemic-fueled business boom cooled down, its revenue and visit growth slowed down considerably while it remained unprofitable.
Teladoc Expands Specialty Care Access With Carrum Health Partnership
TDOC partners with Carrum Health in a bid to expand access to specialty care.
